AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03865563
Drug: Retrograde venous infusion of gemcitabine/lipiodol
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
Trial: NCT03256695
Drug: Albuterol sulfate (ABS)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
Trial: NCT00959231
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00959231
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177760
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00959231
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02814565
Drug: Cyclobenzaprine HCl
RxNorm normalized name: cyclobenzaprine HCl
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine HCl extended-release capsules
Trial: NCT01882907
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: vildagliptin 50mg bid for 16 weeks
Trial: NCT01882907
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15mg bid for 16 weeks
Trial: NCT02672566
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
Trial: NCT01340209
Drug: Tiotropium Respimat
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium high dose once daily delivered with Respimat inhaler
Trial: NCT01340209
Drug: Tiotropium Respimat
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium low dose once daily delivered with Respimat inhaler
Trial: NCT04313764
Drug: Bupivacaine Hcl 0.25% ESP block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
Trial: NCT04313764
Drug: Bupivacaine Hcl 0.25% infiltration
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 20 ml %0.25 bupivacaine
Trial: NCT01587079
Drug: PT003
RxNorm normalized name: Tiotropium bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PT003 MDI administered as two puffs BID for 7 days
Trial: NCT01587079
Drug: PT001
RxNorm normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PT001 MDI administered as two puffs BID for 7 days
Trial: NCT01587079
Drug: PT005
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PT005 MDI administered as two puffs BID for 7 days
Trial: NCT01587079
Drug: Tiotropium inhalation powder
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
Trial: NCT04077827
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
Trial: NCT00284791
Drug: Lamotrigine (drug)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284791
Drug: sertraline (drug)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01631552
Drug: Sacituzumab Govitecan-hziy (SG)
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered via intravenous (IV) infusion
Trial: NCT02163018
Drug: HAL-MPE1
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of increasing doses of HAL-MPE1
Trial: NCT00191815
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
Trial: NCT00191815
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
Trial: NCT02982577
Drug: Pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
Trial: NCT01294800
Drug: Preladenant
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2, 5, or 10 mg tablets taken orally twice daily (BID)
Trial: NCT01294800
Drug: Placebo tablet to match Preladenant
RxNorm normalized name: placebo Oral Tablet
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets taken orally BID
Trial: NCT00876993
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
Trial: NCT00876993
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
Trial: NCT00876993
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
Trial: NCT01208935
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01208935
Drug: Nicotine Gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00926835
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 weeks, 20-50mg/day
Trial: NCT00926835
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20mg/day for 6 weeks
Trial: NCT00926835
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75-225mg/day for 6 weeks
Trial: NCT00926835
Drug: Paroxetine+Bupropion
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
Trial: NCT00926835
Drug: Paroxetine+Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
Trial: NCT00926835
Drug: Paroxetine+Lithium
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
Trial: NCT00926835
Drug: Escitalopram+Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
Trial: NCT00926835
Drug: Escitalopram+Aripiprazole
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
Trial: NCT00926835
Drug: Paroxetine + Venlafaxine XR
RxNorm normalized name: paroxetine Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
Trial: NCT04503902
Drug: Donafenib Tosilate Tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
Trial: NCT04503902
Drug: Toripalimab Injection
RxNorm normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
Trial: NCT00002562
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01880736
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Trial: NCT01880736
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Trial: NCT01880736
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Trial: NCT03520036
Drug: MT-7117 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MT-7117 low dose QD, oral, 16 weeks
Trial: NCT03520036
Drug: MT-7117 high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-7117 high dose QD, oral, 16 weeks
Trial: NCT00012259
Drug: troxacitabine
RxNorm normalized name: Troxacitabine
DrugBank: Troxacitabine (DB04961)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01227421
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
Trial: NCT01227421
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
Trial: NCT00764582
Drug: 1.5% levofloxacin ophthalmic solution
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery
Trial: NCT00764582
Drug: 0.5% moxifloxacin ophthalmic solution
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery
Trial: NCT00000559
Drug: estrogen replacement therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000559
Drug: hormone replacement therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000559
Drug: medroxyprogesterone
RxNorm normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02203032
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
Trial: NCT02203032
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
Trial: NCT02203032
Drug: Placebo for ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
Trial: NCT02203032
Drug: Placebo for guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
Trial: NCT01507272
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
Trial: NCT01507272
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
Trial: NCT00835471
Drug: erlotinib plus docetaxel or pemetrexed
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
Trial: NCT00835471
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erlotinib 150 mg/day continuously until disease progression
Trial: NCT02706873
Drug: Placebo to Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; Oral
Trial: NCT02706873
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; Oral
Trial: NCT01241214
Drug: ACT-129968
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
Trial: NCT01241214
Drug: ACT-129968
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACT-129968 (Dose 4) \& matching placebo administered orally once daily
Trial: NCT01241214
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceterizine administered once daily
Trial: NCT02997995
Drug: Immune-attractant
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
Trial: NCT02095054
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.
Trial: NCT02095054
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.
Trial: NCT03198026
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02997995
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
Trial: NCT00328770
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
Trial: NCT01937650
Drug: Radiotherapy plus metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole was added to the standard radiotherapy that is routinely used.
Trial: NCT02982161
Drug: MR308
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
Trial: NCT02982161
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
Trial: NCT00010361
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00010361
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00010361
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02577510
Drug: Nerve Injection- Nerve Stimulator
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
Trial: NCT02577510
Drug: Nerve Injection - Ultrasound
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
Trial: NCT00672984
Drug: immediate release guanfacine hydrochloride
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.